1 – 14 of 14
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
(
- Contribution to journal › Article
- 2011
-
Mark
TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia
(
- Contribution to journal › Article
- 2010
-
Mark
Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors
(
- Contribution to journal › Article
-
Mark
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk
(
- Contribution to journal › Article
-
Mark
High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors
(
- Contribution to journal › Article
-
Mark
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk
(
- Contribution to journal › Article
- 2009
-
Mark
LPL Is the Strongest Prognostic Factor in a Comparative Study of RNA-Based Markers in Chronic Lymphocytic Leukemia
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
High Resolution Screening of Copy-Number Alterations in Chronic Lymphocytic Leukemia Using Affymetrix 250K SNP-Arrays Reveals a Higher Complexity of Genomic Alterations in Patients with Unmutated IGHV Genes
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
-
Mark
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-A comparative study of four differently designed, high resolution microarray platforms.
(
- Contribution to journal › Article
- 2005
-
Mark
Radioimmunoterapi ved non-Hodgkins lymfom
(
- Contribution to journal › Article